ArticleBiologics : targets & therapy2008
Infliximab in ulcerative colitis.
Article in Biologics : targets & therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta-analysis.United European gastroenterology journal · 2022Pooled it
- Advances in the Treatment of Ulcerative Colitis-From Conventional Therapies to Targeted Biologics and Small Molecules.International journal of molecular sciences · 2026Review
- Highlights in Ulcerative Colitis From the American College of Gastroenterology 2023 Annual Scientific Meeting: Commentary.Gastroenterology & hepatology · 2023Article
- Meroterpenoid-Rich Ethanoic Extract ofFoods (Basel, Switzerland) · 2022Article
- Can molecular stratification improve the treatment of inflammatory bowel disease?Pharmacological research · 2019Review
- Targeting IL-13 as a Host-Directed Therapy Against Ulcerative Colitis.Frontiers in cellular and infection microbiology · 2018Review
- Post-Transcriptional Regulation of Hepatic DDAH1 with TNF Blockade Leads to Improved eNOS Function and Reduced Portal Pressure In Cirrhotic Rats.Scientific reports · 2017Article
- T0001, a variant of TNFR2-Fc fusion protein, exhibits improved Fc effector functions through increased binding to membrane-bound TNFα.PloS one · 2017Article
- C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study.BMC gastroenterology · 2015Article
- Keratinocyte growth factor gene therapy ameliorates ulcerative colitis in rats.World journal of gastroenterology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infliximab, a monoclonal anti-TNF-alpha antibody, is commonly used for treatment of moderate to severe Crohn's disease (CD). Its role in the treatment for ulcerative colitis (UC) remains controversial. We review the role of TNF-alpha in the pathogenesis of UC and describe the randomized, double-blind, placebo-controlled trials and systematic reviews that assess the efficacy of infliximab in the treatment of moderate to severe UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.